Is Bosutinib included in medical insurance?

As of now, Bosutinib has not been included in China’s national medical insurance directory. The main reason is that the original version of the drug has not yet been officially launched in China, so it cannot pass drug registration approval and enter the medical insurance negotiation process. Bosutinib is an oral tyrosine kinase inhibitor (TKI) developed by Pfizer to treat certain types of cancer such as chronic myeloid leukemia (CML). It blocks abnormal signaling pathways by inhibiting BCR-ABL kinase activity, thereby inhibiting the growth and division of tumor cells.

In overseas markets, bosutinib has been approved by the U.S.FDA and European EMA, and has been included in multinational guidelines as one of the treatment options for CML. However, the launch process in the Chinese market is relatively lagging behind. Currently, patients mainly obtain drugs through overseas purchase or international pharmacy channels.

In the overseas market, the original drug of bosutinib mainly includes the Turkish version, the European version and the Swiss version. The packaging specifications and selling prices vary greatly in different countries. For example, the Turkish version is generally considered to be more cost-effective, while the Swiss version represents the high-end quality of the original drug. In addition to the original version, countries such as India have also launched legal generic drugs, whose main active ingredients are the same as the original version and are relatively affordable, providing an alternative for some patients. Although the chemical structure and efficacy of generic drugs are similar, there are still certain differences from the original drugs in terms of drug purity, stability and regulatory standards.

In the future, if bosutinib is successfully approved for marketing in China, the possibility of entering the reimbursement directory will depend on clinical needs assessment, cost-benefit analysis and the outcome of reimbursement negotiations. At present, the national medical insurance policy pays more and more attention to the accessibility of innovative drugs and anti-cancer targeted drugs. If bosutinib shows its advantages in clinical efficacy and economics, the prospect of including it in medical insurance in the future is still promising.

Reference materials:https://go.drugbank.com/drugs/DB06616